CTI Clinical Trial and Consulting Services
(CTI) announces its collaboration with
Galectin Therapeutics
on a first-in-man Phase I clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH or fatty liver disease) with advanced fibrosis.
The Phase 1 clinical trial is entitled, "A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced Hepatic Fibrosis," and will be conducted in six centers in the United States, all of which have extensive experience in conducting liver disease trials. The trial investigator kick-off meeting was held in Atlanta, GA on April 5, 2013, and it is anticipated that the enrollment and infusion of the first cohort will be completed by the end of Q2 2013.
“CTI is excited to be a part of such a groundbreaking clinical trial that will help a significant and progressive unmet medical need,” according to Lynn Fallon, Executive Vice President and President, Consulting at CTI. “NASH affects between 9 and 15 million people in the United States, and is the third leading indication for liver transplantation. This trial will be critical to helping patients where there is currently no approved medical therapy. CTI has extensive experience in liver disease, fibrosis, and in conducting first-in-human trials.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.